Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pranlukast. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 known ✓ | Q9Y271 | 17/20 | 0.76 |
| ▸ | CYSLTR2 | Q9NS75 | 17/20 | 0.76 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.75 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.75 |
| ▸ | PGR | P06401 | 1/20 | 0.75 |
| ▸ | HTR1A | P08908 | 1/20 | 0.75 |
| ▸ | AR | P10275 | 1/20 | 0.75 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.75 |
| ▸ | DRD1 | P21728 | 1/20 | 0.75 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.75 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.75 |
| ▸ | PDE4A | P27815 | 1/20 | 0.75 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.75 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.75 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.75 |
| ▸ | DRD3 | P35462 | 1/20 | 0.75 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.75 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.75 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.75 |
| ▸ | RUVBL1 | Q9Y265 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pranlukast SCHEMBL4467007 | 1.00 | CYSLTR2 (0.76) | CYSLTR2CYSLTR1ABCC4ABCB11PGR | |
| Pranlukast SCHEMBL31756724 | 0.99 | CYSLTR2 (0.76) | CYSLTR2CYSLTR1ABCC4ABCB11PGR | |
| Pranlukast SCHEMBL3693 | 0.99 | CYSLTR2 (0.76) | CYSLTR2CYSLTR1ABCC4ABCB11PGR | |
| Pranlukast SCHEMBL15546550 | 0.98 | CYSLTR2 (0.75) | CYSLTR2CYSLTR1ABCC4ABCB11PGR | |
| SCHEMBL6960848 | 0.98 | CYSLTR2 (0.75) | CYSLTR2CYSLTR1ABCC4ABCB11PGR | |
| SCHEMBL8163711 | 0.97 | CYSLTR2 (0.76) | CYSLTR2CYSLTR1ABCC4ABCB11PGR | |
| Pranlukast SCHEMBL29227539 | 0.95 | CYSLTR2 (0.71) | CYSLTR2CYSLTR1ABCC4ABCB11PGR | |
| SCHEMBL8149103 | 0.91 | CYSLTR2 (0.64) | CYSLTR2CYSLTR1ABCC4ABCB11PGR | |
| SCHEMBL7474226 | 0.90 | CYSLTR2 (0.63) | CYSLTR2CYSLTR1ABCC4ABCB11PGR | |
| Pranlukast SCHEMBL19816814 | 0.90 | CYSLTR2 (0.64) | CYSLTR2CYSLTR1ABCC4ABCB11PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2848243-B1 | ORGANIC COMPOUND NANOPOWDER, PRODUCTION METHOD THEREFOR, AND SUSPENSION | ACTIVUS PHARMA CO LTD (JP) | 2023-07-12 | — | — | EP | claimed |
| EP-3936131-A1 | COMPOUNDS FOR THE TREATMENT OF ZIKA | Dompe' Farmaceutici S.P.A. (IT) | 2022-01-12 | — | — | EP | claimed |
| CN-107735401-B | Substituted dihydropyrrolopyrazole derivatives | 宇部兴产株式会社 | 2021-08-31 | — | — | CN | claimed |
| US-20190216790-A1 | Methods for Treating Pruritis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-07-18 | — | — | US | claimed |
| US-10273252-B2 | Substituted dihydropyrrolopyrazole derivative | UBE INDUSTRIES, LTD. (JP) | 2019-04-30 | — | — | US | claimed |
| US-20180186818-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2018-07-05 | — | — | US | claimed |
| WO-2018071687-A1 | METHODS OF TREATING PRURITIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-04-19 | — | — | WO | claimed |
| EP-3309163-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE Industries, Ltd. (JP) | 2018-04-18 | — | — | EP | claimed |
| CN-107735401-A | Substituted Dihydropyrrolopyrazole Derivatives | 宇部兴产株式会社 | 2018-02-23 | — | — | CN | claimed |
| US-9782484-B2 | Method for producing a composite organic compound powder for medical use | ACTIVUS PHARMA CO., LTD. (JP) | 2017-10-10 | — | — | US | claimed |
| US-20120237768-A1 | METHOD FOR PRODUCING PULVERIZED ORGANIC COMPOUND PARTICLE | ACTIVUS PHARMA CO., LTD. (JP) | 2012-09-20 | — | — | US | claimed |
| US-8226983-B2 | Method for producing pulverized organic compound particle | ACTIVUS PHARMA CO., LTD. (JP) | 2012-07-24 | — | — | US | claimed |
| CN-102149410-A | Composite organic compound powder for medical use, method for producing same and suspension of same | ACTIVUS PHARMA CO LTD | 2011-08-10 | — | — | CN | claimed |
| EP-2345426-A1 | COMPOSITE ORGANIC COMPOUND POWDER FOR MEDICAL USE, METHOD FOR PRODUCING SAME AND SUSPENSION OF SAME | Activus Pharma Co., Ltd. (JP) | 2011-07-20 | — | — | EP | claimed |
| US-20110165259-A1 | COMPOSITE ORGANIC COMPOUND POWDER FOR MEDICAL USE, METHOD FOR PRODUCING SAME AND SUSPENSION OF SAME | ACTIVUS PHARMA CO., LTD. (JP) | 2011-07-07 | — | — | US | claimed |
| EP-1010435-B1 | NANOCAPSULE PREPARATIONS FOR TREATING INTRAARTICULAR DISEASES | MARUHO K K (JP) | 2010-11-03 | — | — | EP | claimed |
| CN-101636150-A | Method for producing pulverized organic compound particle | ACTIVUS PHARMA CO LTD | 2010-01-27 | — | — | CN | claimed |
| US-20100016597-A1 | Method for producing pulverized organic compound particle | ACTIVUS PHARMA CO., LTD. (JP) | 2010-01-21 | — | — | US | claimed |
| EP-2143423-A1 | METHOD FOR PRODUCING PULVERIZED ORGANIC COMPOUND PARTICLE | Activus Pharma Co., Ltd. (JP) | 2010-01-13 | — | — | EP | claimed |
| US-20070249695-A1 | Preventive and/or Therapeutic Agents for Meniere's Disease | KAZUYA KAWATA (JP) | 2007-10-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249695-A1 | Preventive and/or Therapeutic Agents for Meniere's Disease | MEN1, LTA4H, LTC4S | CYSLTR1 8/4885CYSLTR2 6/4885ABCC4 1737/4885 |
| US-20190216790-A1 | Methods for Treating Pruritis | ITCH, CYSLTR2, CYSLTR1 | CYSLTR1 3/4885CYSLTR2 2/4885ABCC4 1968/4885 |
| US-10273252-B2 | Substituted dihydropyrrolopyrazole derivative | QDPR, CYP11B2, CYP4F3 | CYSLTR1 3141/4885CYSLTR2 2658/4885ABCC4 122/4885 |
| US-20180186818-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | QDPR, CYP11B2, CYP4F3 | CYSLTR1 3141/4885CYSLTR2 2658/4885ABCC4 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.